- Home
- CHPT vs URGN Comparison
CHPT vs URGN Comparison
Compare CHPT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- URGN
- Stock Information
- Founded
- CHPT 2007
- URGN 2004
- Country
- CHPT United States
- URGN United States
- Employees
- CHPT N/A
- URGN N/A
- Industry
- CHPT Industrial Specialties
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- URGN Health Care
- Exchange
- CHPT Nasdaq
- URGN Nasdaq
- Market Cap
- CHPT 468.9M
- URGN 465.9M
- IPO Year
- CHPT N/A
- URGN 2017
- Fundamental
- Price
- CHPT $0.61
- URGN $11.06
- Analyst Decision
- CHPT Hold
- URGN Strong Buy
- Analyst Count
- CHPT 10
- URGN 6
- Target Price
- CHPT $1.69
- URGN $40.75
- AVG Volume (30 Days)
- CHPT 22.8M
- URGN 418.3K
- Earning Date
- CHPT 03-04-2025
- URGN 03-10-2025
- Dividend Yield
- CHPT N/A
- URGN N/A
- EPS Growth
- CHPT N/A
- URGN N/A
- EPS
- CHPT N/A
- URGN N/A
- Revenue
- CHPT $417,083,000.00
- URGN $90,398,000.00
- Revenue This Year
- CHPT $14.08
- URGN $43.60
- Revenue Next Year
- CHPT $26.64
- URGN $103.77
- P/E Ratio
- CHPT N/A
- URGN N/A
- Revenue Growth
- CHPT N/A
- URGN 9.29
- 52 Week Low
- CHPT $0.56
- URGN $9.03
- 52 Week High
- CHPT $2.44
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- CHPT 35.90
- URGN 50.86
- Support Level
- CHPT $0.66
- URGN $11.12
- Resistance Level
- CHPT $0.71
- URGN $11.91
- Average True Range (ATR)
- CHPT 0.05
- URGN 0.57
- MACD
- CHPT 0.00
- URGN -0.02
- Stochastic Oscillator
- CHPT 22.64
- URGN 26.40
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.